All In MedTech

Device Trial Radar · NCT06999408

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

A Prospective, 8-Month, Randomized Pilot Study of TargetCool™ Cryo-Modulation and BENEV Exosome Regenerative Complex+® for Hair Density Enhancement in Adults With Non-Scarring Hair Thinning

Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Sep 16, 2025

Primary completion

May 2026

Study completion May 2026

Sponsor

Lead sponsor
Recens Medical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Benev Company, Inc.
First posted
May 31, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determine whether this combination approach offers synergistic benefits for individuals with hair thinning. Exosomes are tiny particles that come from stem cells and contain growth factors and other nutrients. They are being studied for their potential to help regenerate skin and hair. TargetCool™ is an FDA-cleared device that uses precision cooling to reduce inflammation and improve comfort. Microneedling is a common, minimally invasive procedure that uses small needles to stimulate the skin and help absorb topical products more effectively. The study will include healthy men (ages 18 to 70) and women (ages approximately 45 to 70) who are not of childbearing potential. A total of 9 to 15 participants will be randomly placed into one of three groups: Group 1: Exosomes with TargetCool™ Group 2: Microneedling followed by exosomes and TargetCool™ Group 3: Microneedling followed by exosomes only Participants will receive four treatments over 9 weeks. Each visit may include microneedling, TargetCool™ treatment, and exosome application depending on group assignment. A small tattoo will be placed on the scalp to help capture consistent photographs, and a special imaging system (Canfield HairMetrix®) will be used to measure hair changes. Participants will return for follow-up visits at 3 and 6 months after the final treatment. The results will help determine whether this combination of cosmetic treatments is safe and beneficial for people experiencing hair thinning.

Conditions

  • Hair Diseases
  • Alopecia
  • Hair Thinning

Interventions

  • Scalp tattooDevice

    A micropigmentation scalp tattoo will be applied at baseline to mark consistent photographic sites.

  • Canfield HairMetrix®Device

    Canfield HairMetrix® imaging will be utilized to capture global and trichoscopic hair measurements.

  • TargetCoolDevice

    Boosting will be used to apply exosomes

  • Microneedle-facilitated lidocaine applicationDevice

    Microneedling will be performed to a depth of 0.5 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Terminal Hair CountsTime frame: 32 weeks (8 months)
  2. Change in Vellus Hair CountsTime frame: 32 weeks (8 months)
  3. Change in Total Hair CountsTime frame: 32 weeks (8 months)

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Marc Avram MD

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.